MSJ Group
Industry
- Pharmaceuticals
- OTC, Consumer
- Nutraceuticals
See more in Biomedtracker
Latest on MSJ Group
In Vivo
• By Amanda Micklus
When a drug developer loses a partner, there's actually a 50-50 chance that the drug will remain in development, according to a new study of deals data from Informa’s Strategic Transactions . And of
In Vivo
IN VITRO DIAGNOSTICS Mergers & Acquisitions Institut Merieux bioMerieux SA BioFire Diagnostics Inc. Leading diagnostics firm bioMerieux SA (a division of Institut Merieux ) has agreed to acquir